Biotechnology Focus Podcast

078 | Investing, combating and treating

Informações:

Sinopse

Welcome to another episode of Biotechnology Focus radio. This week we are discussing a recent investment, the engineering of a CAR molecule to combat cancer, a new surgical treatment and a study notifying us that viruses are literally falling to Earth. I am your host Michelle Currie, here to bring you the lowdown on the Canadian biotech scene. +++++ Ontario Genomics is investing $100,000 in one of Toronto’s newest start-up companies, Bright Angel Therapeutics to develop anti-fungal treatments. Fungal diseases are a growing global public health problem. Data compiled by the Global Action Fund for Fungal Infections shows that “over 300 million people are afflicted with a serious fungal infection and 25 million are at high risk of dying or losing their sight.” Mortality due to fungal infections is primarily due to the development of resistance to the few available anti-fungal compounds. Ontario Genomics’ Pre-commercial Business Development Fund investment will help Bright Angel Therapeutics develop new compounds